aTyr Pharma(ATYR)

Focus: aTyr Pharma is a public-stage biotech focused on therapeutic proteins for respiratory and infectious disease indications. The company is pre-revenue or near-zero revenue with a highly experimental pipeline.

Respiratory Infectious Diseases

Profile data last refreshed 14h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About aTyr Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow aTyr Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$353K

Pipeline & Clinical Trials

A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Lif

Facioscapulohumeral Muscular Dystrophy

N/A

Clinical Trials (1)

NCT01437345A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD

N/A

Help build intelligence for aTyr Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leadership in niche therapeutic protein space (efzofitimod platform) with Phase 3 advancement in pulmonary sarcoidosis offering real clinical validation potential.
Multiple clinical programs across muscular dystrophy, infectious disease, and respiratory indications create diverse career trajectory opportunities.
Public company status provides equity upside visibility and institutional stability versus private biotech.

Watch Out For

Severe financial distress: $50M+ annual net losses, only $23M cash on hand (FY 2025), and near-zero product revenue ($353K) creates acute burn-rate risk and restructuring likelihood.
Extremely limited hiring activity (zero active job postings) suggests workforce constraints or frozen recruitment amid financial pressure.
Highly speculative pipeline with only 1 Phase 3 program; 6 Phase 1 and 8 Phase 2 programs represent years of clinical uncertainty with no near-term commercial catalysts.

Generated by Claude from aTyr Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ATYR1940

Facioscapulohumeral Muscular Dystrophy

PHASE_1_2

Clinical Trials (1)

NCT02531217Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

Phase 1/2

ATYR1940

Facioscapulohumeral Muscular Dystrophy (FSHD)

PHASE_1_2

Clinical Trials (1)

NCT02603562Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

Phase 1/2

ATYR1940

Limb-Girdle Muscular Dystrophies

PHASE_1_2

Clinical Trials (1)

NCT02579239Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 1/2

Efzofitimod 1.0 mg/kg or Placebo

Pulmonary Sarcoidosis

PHASE_1_2

Clinical Trials (1)

NCT03824392Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Phase 1/2

ATYR1940

Facioscapulohumeral Muscular Dystrophy

PHASE_1_2

Clinical Trials (1)

NCT02836418Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 1/2

Placebo

Facioscapulohumeral Muscular Dystrophy (FSHD)

PHASE_1_2

Clinical Trials (1)

NCT02239224Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Phase 1/2

efzofitimod 450 mg

Interstitial Lung Disease

PHASE_2

Clinical Trials (1)

NCT05892614Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Phase 2

Efzofitimod 1 mg/kg

SARS-CoV-2 (COVID-19) Severe Pneumonia

PHASE_2

Clinical Trials (1)

NCT04412668Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Phase 2

Efzofitimod 3 mg/kg

Pulmonary Sarcoidosis

PHASE_3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 9 clinical trials

Top TAs: Respiratory, Infectious Diseases

Publications: 25 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Respiratory

2 pipeline

Infectious Diseases

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$353K97%

R&D Spend

$42M(11981%)1%

Net Income

-$50M

Risk Signals

Recent news reports (May 2026) cite rising short interest and market pressure on earnings; no formal layoff announcement disclosed, but financial trajectory suggests restructuring risk within 12 months.

Elevated financial and operational risk; stock volatility and short interest activity signal investor concerns about solvency and clinical trial outcomes.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Histidine Supplementation Stabilizes Hearing and Vision and Improves Growth in HARS1-Related Autosomal Recessive Disorder Associated With Usher-Like Symptoms.

American journal of medical genetics. Part A

2026

PMID:42157369

A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F.